PAnTHA
A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC) Nature and objective :The PAnTHA study aims to assess the safety, tolerance, pharmacokinetics, and preliminary efficacy of 225Ac-PSMA-Trillium, a targeted alpha therapy that is a new class of […]
Ironman
IRONMAN: International registry for men with advanced prostate cancer Nature and objective :This is a registry for people who have been diagnosed with metastatic hormone-sensitive prostate cancer (mCPHS) or non-metastatic (M0) castration-resistant prostate cancer (CRPC) or metastatic (M1). The goal of this research project is to learn more about prostate cancer and: To describe the use […]
